Eli Lilly (LLY) Revenue (2009 - 2026)

Eli Lilly has reported Revenue for 18 years, with the latest figure at $19.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 55.54% year-over-year to $19.8 billion; the trailing twelve-month figure through Mar 2026 stood at $72.2 billion (up 47.44% YoY), and the FY2025 full-year result was $65.2 billion, up 44.7% from the prior year.
• Revenue for Q1 2026 stood at $19.8 billion, up from $19.3 billion in the prior quarter.
• The five-year high for Revenue was $19.8 billion in Q1 2026, with the low at $6.5 billion in Q2 2022.
• Historically, Revenue has averaged $11.3 billion across 5 years, with a median of $9.5 billion in 2023.
• Annual changes were most pronounced in 2023 — Revenue declined 10.88% — and 2026, when it jumped 55.54%.
• Eli Lilly's Revenue stood at $7.3 billion in 2022, then gained by 28.1% to $9.4 billion in 2023, then soared by 44.69% to $13.5 billion in 2024, then jumped by 42.55% to $19.3 billion in 2025, then increased by 2.63% to $19.8 billion in 2026.
• The last three Revenue figures came in at $19.8 billion (Q1 2026), $19.3 billion (Q4 2025), and $17.6 billion (Q3 2025), per Business Quant data.